Effect of daclizumab, tacrolimus and mycophenolate mofetil in racial minority first renal transplant recipients

Transplant Proc. 2002 Aug;34(5):1617-8. doi: 10.1016/s0041-1345(02)03045-2.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Black People
  • Black or African American
  • Cadaver
  • Cause of Death
  • Daclizumab
  • Florida
  • Follow-Up Studies
  • Graft Rejection / epidemiology
  • Hispanic or Latino
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / mortality
  • Living Donors
  • Middle Aged
  • Minority Groups*
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use*
  • Retrospective Studies
  • Survival Rate
  • Tacrolimus / therapeutic use*
  • Time Factors
  • Tissue Donors
  • Treatment Failure
  • Treatment Outcome
  • White People

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Daclizumab
  • Mycophenolic Acid
  • Tacrolimus